Shanghai Pharmaceuticals Holding Co., Ltd. (“SPH”) is a vertically-integrated and diversified pharmaceutical group. The company has dual listings on the stock exchanges in Shanghai (601607) and Hong Kong (02067) respectively. The company provides leading healthcare services in: Research & Development, Manufacturing, Distribution and Retail.
In 2023, SPH reported revenues of US$36.9bn, and it ranked 438th on the 2023 Global Fortune 500 list, making the company one of the country’s major forces in the industry. SPH is one of the few listed pharmaceutical companies with a leading position in both manufacturing and distribution in China. It is included in the constituent stocks of the SSE 180, CSI 300 index and MSCI.
Company Details
- Employees
- 9
- Address
- 89 Aia Capital Center, Ratchadaphisek R., Din Daeng, Bangkok,10400,thailand
- Industry
- International Trade And Development
- NAICS
-
International Trade Financing
- Keywords
- in: Research & Development.
- HQ
- Bangkok
Shanghai Pharma Asean Questions
Shanghai Pharma Asean's LinkedIn profile is https://th.linkedin.com/company/shanghai-pharma-asean
Shanghai Pharma Asean has
9 employees.
View email and phone details for 9
employees at Shanghai Pharma Asean.
Shanghai Pharma Asean's industry is
International Trade and Development
Shanghai Pharma Asean's top competitors are
Daewoong Pharmaceutical (Thailand) Co., Ltd.,
Dksh,
Fosun Pharma,
Sun Pharma,
Amgen,
Wuxi Apptec,
B. Braun Group,
Wuxi Biologics,
Shanghai Pharmaceuticals Holding Co., Ltd.,
Hengrui Pharma.
Shanghai Pharma Asean's categories are International Trade and Development
